M&A Deal Summary

uniQure Acquires Corlieve Therapeutics

On June 22, 2021, uniQure acquired life science company Corlieve Therapeutics for 46M EUR

Acquisition Highlights
  • This is uniQure’s 3rd transaction in the Life Science sector.
  • This is uniQure’s 0th largest (disclosed) transaction.
  • This is uniQure’s 1st transaction in France.

M&A Deal Summary
Date 2021-06-22
Target Corlieve Therapeutics
Sector Life Science
Buyer(s) uniQure
Deal Type Add-on Acquisition
Deal Value 46M EUR
Advisor(s) McDermott Will & Emery (Legal)

Target

Corlieve Therapeutics

Paris, France
website
Corlieve Therapeutics is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders. The lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with refractory TLE using a gene therapy approach. Corlieve was founded by Kurma Partners 4Q2019 on the basis of a partnership with REGENXBIO Inc., SATT Aquitaine Science Transfert, and Inserm Transfert. Corlieve Therapeutics was founded in 2019 is based in Paris, France.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

uniQure

Amsterdam, Netherlands

website

Category Company
Founded 1998
Sector Life Science
Employees463
Revenue 524M USD (2021)
DESCRIPTION

uniQure is a gene therapy company that developed the first and only gene therapy product to receive regulatory approval in the European Union. Gene therapy is a technique for correcting defective or missing genes that cause diseases. uniQure is primarily focused on rare genetic diseases, and will also start developing gene therapies for chronic and degenerative diseases that affect larger populations. uniQure was founded in 1998 and is based in Amsterdam, the Netherlands.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 3 of 3
Country (France) 1 of 1
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-11 InoCard

Heidelberg, Germany

InoCard GmbH is a biotechnology company focused on the development of gene therapy approaches for cardiac disease.

Buy €3M
Mergr

Product

Company

Legal